AllSci News
Kelun-Bio moving TAA-PD-L1 bispecific ADC into clinic in China
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) announced that its Investigational New Drug application for SKB103, a tumor associated antigen (TAA)/PD-L1 bispecific antibody-drug…
Gilead moves on Ouro’s BCMA TCE for up to USD 2.2b with Galapagos in line to support
Gilead Sciences announced a definitive agreement to acquire San Francisco-based Ouro Medicines in a deal worth up to USD 2.175 billion. The…
Calidi to advance IL-15-armed onco virus into first-in-human in Australia
Calidi Biotherapeutics, based in San Diego, has engaged Avance Clinical, a full-service contract research organization (CRO), to facilitate Australian regulatory approval and…
Amani raises USD 25m Series A, in-licenses AZ compound for clozapine FDC
Amani Therapeutics, a newly formed biotechnology company based in New York, has closed a USD 25 million Series A financing round to…
BMS picks two AI-discovered ALS targets from insitro collaboration
insitro and Bristol Myers Squibb expanded their option-based discovery collaboration in amyotrophic lateral sclerosis (ALS), with Bristol Myers Squibb (BMS) nominating two…
Aspen makes late breaking presentation of sasineprocel’s improvements in early trial for Parkinson’s
Aspen Neuroscience reported 12-month data from the ASPIRO clinical trial evaluating sasineprocel (ANPD001), an autologous iPSC-derived dopaminergic neuron precursor cell therapy, in…
Pfizer and Valneva aim to file Lyme disease vaccine despite statistical fail in Phase III
Pfizer (NYSE: PFE) and Valneva (Nasdaq: VALN) reported Phase III results for their Lyme disease vaccine candidate PF-07307405 (LB6V, formerly VLA15), showing…
Verily secures USD 300m to scale AI health platform, signaling strategic shift from Alphabet
Verily Health Inc., a precision health technology company headquartered in Dallas, TX, has closed a USD 300 million investment round to fund…
Pfizer calls halt to Phase I development of Seagen-acquired CD228 ADC
Pfizer has terminated its Phase I PF-08046031 clinical trial in adults with advanced melanoma and other solid tumors, according to an update…
Novo Nordisk adds high-dose Wegovy option in the US
The US FDA has approved Wegovy HD (semaglutide) 7.2 mg for weight loss and long-term weight maintenance in certain adults with obesity,…
ImmunoBrain posts early safety data for PD-L1 against Alzheimer’s
ImmunoBrain, a New York–based clinical-stage company, presented Phase Ib data for IBC-Ab002, an anti-PD-L1 monoclonal antibody in early Alzheimer’s disease, at the…
Triana’s brain-penetrant molecular glue degrader TRI-611 enters clinic set for ALK+ NSCLC
Triana Biomedicines, a privately held biotechnology company based in Lexington, Massachusetts, has dosed the first patient in a Phase I/II clinical trial…
Congruence raises USD 39.5m to advance protein misfolding correctors to clinic
Congruence Therapeutics, a Montreal-based biotechnology company developing small molecule correctors for diseases of protein misfolding, has closed a USD 39.5 million financing…
Endevica spins out Kalohexis to advance melanocortin-targeted obesity and cachexia therapies
Illinois-based Endevica Bio announced the spinout of Kalohexis, a new clinical-stage biotech focused on developing therapies targeting the melanocortin system for metabolic…
Atrogi’s GRK-biased β2 agonist enters clinic aiming to achieve muscle-sparing fat loss
Stockholm-based Atrogi AB has dosed the first subjects in clinical trial evaluating the muscle physiological effects of its oral β2-adrenergic receptor therapy…
The AllSci Brief
Free, systematic R&D and deal news. Daily.